A proof of concept study to evaluate the treatment response of aflibercept in wARMD using OCT-A (Canada study)

Purpose To Utilize OCT-A to measure the change in size (mm 2 ) and density (flow index) of choroidal neovascular membranes (CNVMs) from baseline to week 52 of treatment-naïve wet age-related macular degeneration (wARMD) patients receiving intravitreal aflibercept injections (IAI). Methods Patients w...

Full description

Saved in:
Bibliographic Details
Published in:International ophthalmology 2021-05, Vol.41 (5), p.1697-1708
Main Authors: Sodhi, Simrat K., Trimboli, Carmelina, Kalaichandran, Sivaruben, Pereira, Austin, Choudhry, Netan
Format: Article
Language:English
Subjects:
Acuity
Age
Age related diseases
Biomarkers
Blood vessels
Density
Diabetic retinopathy
Evaluation
Eye diseases
Iodine
Learning algorithms
Machine learning
Macular degeneration
Medical imaging
Medicine
Medicine & Public Health
Ophthalmology
Original Paper
Patients
Perfusion
Retina
Segmentation
Subgroups
Surgery
Tomography
Visual acuity
Visual impairment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To Utilize OCT-A to measure the change in size (mm 2 ) and density (flow index) of choroidal neovascular membranes (CNVMs) from baseline to week 52 of treatment-naïve wet age-related macular degeneration (wARMD) patients receiving intravitreal aflibercept injections (IAI). Methods Patients were treated with IAI at baseline, month 1 and month 2 and then every other month for a total of 12 months. Along with clinical examination and best corrected visual acuity (BCVA), OCT-A 6- and 3-mm scans were acquired at every visit between May 2017 and January 2019. Data from baseline, week 12 and week 52 were analyzed prospectively and included in the final analysis. Results Twenty-five eyes from 23 patients were included in the study. The mean BCVA at baseline and week 52 increased from 20/125 to 20/80, respectively ( p  
ISSN:0165-5701
1573-2630
DOI:10.1007/s10792-021-01726-z